November 13, 2015 – Plaintiffs, Cleveland Clinic Foundation and Cleveland Heartlab, Inc. (collectively, “Cleveland”) filed a complaint against True Health Diagnostics LLC (“True Health”), asserting infringement of U.S. Patent Nos. 7,223,552 (“Myeloperoxidase, A Risk Indicator For Cardiovascular Disease”); 7,459,286 (“Assessing the Risk of a Major Adverse Cardiac Event in Patients with Chest Pain”); and 8,349,581 (“Assessing the Risk of a Major Adverse Cardiac Event in Patients with Chest Pain”) in the United States District Court of the Northern District of Ohio. Cleveland asserts that it is owner of all rights and interests related to the asserted patents. All three patents are directed and related to Cleveland’s blood test kits for cardiovascular disease called, Myeloperoxidase. According to the Complaint, the action arises from True Health using, performing, and/or selling Myeloperoxidase test services and kits. The case remains pending and is captioned, Cleveland Clinic Foundation et al v. True Health Diagnostics LLC, 1-15-cv-02331 (OHND).
By: H. Rachael Million-Perez